Bupivacaine transdermal - DURECT

Drug Profile

Bupivacaine transdermal - DURECT

Alternative Names: DUR-843; ELADUR; IPX-239; TRANSDUR®-Bupivacaine

Latest Information Update: 21 Dec 2015

Price : $50

At a glance

  • Originator DURECT Corporation; EpiCept Corporation
  • Developer DURECT Corporation
  • Class Anilides; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Postherpetic neuralgia
  • New Molecular Entity No

Highest Development Phases

  • Phase II Postherpetic neuralgia
  • Discontinued Back pain

Most Recent Events

  • 21 Dec 2015 Phase-II development for Postherpetic neuralgia is ongoing in USA
  • 31 Aug 2015 Phase-II development for Postherpetic neuralgia is ongoing in USA
  • 07 Jan 2014 Bupivacacine transdermal licensed to IMPAX Laboratories worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top